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Medicine, Department of Pharmacology, Charles University, Prague, Czech RepublicA B S T R A C TObjective: International pharmacoeconomic studies suggest that
functional impairment can be a signiﬁcant predictor for the evalua-
tion of direct and productivity costs for rheumatoid arthritis (RA). We
calculated the direct and productivity costs for ﬁve Health Assess-
ment Questionnaire (HAQ) groups of patients (HAQ scores o0.6, 0.6Z
1.1, 1.1 Z 1.6, 1.6 Z 2.1, and Z2.1) in the Czech Republic. Methods:
This was a retrospective cross-sectional study. We included 261
patients with RA, aged 18 to 84 years. We applied a bottom-up
method by retrospectively reviewing individual patient medical
records. Patients’ demographic characteristics, patient-reported out-
come, and clinical parameters were gathered at the time of data
collection. For the calculation of productivity costs, we used the
friction cost approach, based on patient absenteeism with a friction
period of 130 workdays, with average monthly income used as the
denominator. Costs were expressed as a mean value per patient with
RA in each HAQ group. Results: Mean patient age was 56.4 years.ee front matter Copyright & 2014, International S
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blic.average time from diagnosis was 14.5 years, the mean HAQ score was
1.15, and the Disease Activity Score in 28 joints was 3.45. A total of
47.5% patients were treated with biologics. Mean annual direct
medical costs for each HAQ group were €5315, €7357, €7697, €7716,
and €8968, respectively. The mean annual indirect costs associated
with productivity loss were €1414, €1459, €1610, €1876, and €2307,
respectively. Conclusions: Direct costs and productivity costs for
patients with RA are closely related to the value of the HAQ score.
The annual mean total (direct plus productivity) costs per patient 1)
treated with biologics, 2) without biologic treatment, and 3) from the
overall cohort were €14,763, €3,559, and €8,882, respectively.
Keywords: cost-of-illness, health economics, quality of life, rheumatoid
arthritis.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Rheumatoid arthritis (RA) is a chronic progressive autoimmune
disease associated with gradual destruction of bone and articular
structures and loss of function and sometimes requires joint
replacements, all of which can result in signiﬁcantly reduced
quality of life and premature death. RA affects 0.7% to 1.0% of the
adult population [1–3], and it represents a substantial cost to both
public health insurance and societal resources, making it a
signiﬁcant economic issue [4–6].
The results of international pharmacoeconomic studies sug-
gest that functional impairment measured by the Health Assess-
ment Questionnaire (HAQ) is an important predictor of direct
costs (health care–related or medical) as well as indirect costs
(related to loss of work productivity) [7–9].
The HAQ is a speciﬁc questionnaire or instrument used to
measure the quality of life of patients with RA that is straightfor-
ward and easy to complete. Therefore, the HAQ is one of the mostwidely used questionnaires for patients with RA [10]. For the
purpose of this study, we used the Czech version of the HAQ,
which was validated in 2010 [11].
In contrast to Western European countries, there have been few
published studies in central and eastern European countries describ-
ing costs (direct and productivity) in relation to patient functional
impairment and disease status (severity) for the diagnosis of RA
[12,13]. These cost studies are crucial for understanding the burden
of the disease, which should be of particular importance to policy-
makers, and simultaneously offer the presteps for cost-effectiveness
modeling of RA, which are usually based on health states relative to
disease severity/functional impairment (i.e., HAQ states).Methods
We performed a bottom-up cross-sectional cost-of-illness study
[14] retrospectively reviewing individual medical records ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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of rheumatic diseases in the Czech Republic (Institute of Rheu-
matology, Prague, which is the biggest and the most specialized
center for the treatment of RA in the Czech Republic). Patients
consecutively coming for regularly scheduled outpatient visits in
turn of the year 2012 and 2013 were evaluated. According to the
study protocol, 50 patients (10) in each of ﬁve HAQ categories
were intended to be included, summing up to approximately 250
patients in the whole study.
Demographic data (including the date when RA was ﬁrst
diagnosed, employment status, and work disability) and clinical
and patient-reported outcomes were reported by participating
physicians. Functional impairment (HAQ scores) data were
obtained from patients after completing the HAQ, representing
time 0 month of the study. These data were gathered at time 0
month (i.e., time of data collection) together with data for all
resources used during the previous 6 or 12 months (the 12-month
period refers to biologic treatment only). All resources used and
cost data were annualized. Hence, the value of patients’ HAQ
score was attributed to health and productivity resources and
costs of the previous year. Patients were divided into ﬁve
categories on the basis of HAQ scores measured at time 0 month:
1) o0.6, 2) 0.6 Z 1.1, 3) 1.1 Z 1.6, 4) 1.6 Z 2.1, and 5) Z2.1.
For the data recording, we used an online electronic case
report form to ensure availability of all data required.
Resource Utilization and Use
The direct cost analysis was based on records of all resources
drawn upon from the public health insurance fund for a partic-
ular patient. Only resources directly related to RA were recorded;
for example, only medicines and outpatient and inpatient visits
directly related to the diagnosis of RA were considered to be
relevant for our study. The decision of which resources to
include/exclude related to RA was taken by the attending physi-
cians, that is, staff rheumatologists at the clinic.
We also recorded resources use (health care utilization) of
treatment. Detailed data for each of several drug groups (anti–
tumor necrosis factors, other biologics, disease-modifying anti-
rheumatic drugs, corticosteroids, nonsteroidal anti-inﬂammatory
drugs, etc.), including dosing, treatment pattern, and duration of
therapy, were registered; the data also included all changes in
treatment. The recall period for all medicines was 12 months to
prevent a possible bias that can happen with shorter recall
periods, which cannot capture medication changes or discontin-
uation or changes in dosing schemes.
Apart from medicines, other recorded resources were out-
patient visits related to RA (such as the number of ofﬁce visits),
physical therapy, imaging techniques (X-ray, magnetic resonance
imaging, sonography, etc.), surgery and inpatient hospital stays
related to RA, and spa procedures. Except for spa procedures, all
mentioned health care data were obtained with a recall period of
6 months; spa procedures had a recall period of 12 months. Items
that were recorded for the previous 6 months were multiplied by
2 (annualized).
Cost Valuation
Costs were calculated for a full year in Czech crowns (CZK) and
then adjusted for inﬂation using the Eurostat’s Harmonised Index
of Consumer Prices to obtain costs in 2013 CZK. Costs were then
converted to the euro using the mean exchange rate for 2013 (€1
¼ 25.74 CZK; source: Czech National Bank). For 2013, we used the
average Harmonised Index of Consumer Prices and the exchange
rate valid for the ﬁrst 10 months in 2013.
According to resource use, monetary values were subse-
quently assigned. For medicines, we used the ofﬁcial list ofreimbursed medicines established by the State Institute of Drug
Control (effective November 2013). With regard to health care
procedures including inpatient and outpatient visits, the prices
were assigned on the basis of “Public Note of the Czech Ministry
of Health no. 134/1998, Coll. of Acts,” health care procedure list
(amended by later regulations), and “Public Note of the Czech
Ministry of Health no. 396/2010, Coll. of Acts” for the determi-
nation of point values.
Only resources and costs reimbursed from public insurance
were relevant; patient co-payments and out-of-pocket expenses
were not included in the study.
Productivity Costs
With regard to the indirect costs of RA, we focused on produc-
tivity costs (i.e., costs associated with lost productivity). We used
the friction cost approach [15], which is recommended by the
Czech Pharmacoeconomic Association [16]. This method as-
sumes that patients—both with disabilities and prematurely
deceased—will be replaced in their job positions. Work produc-
tivity loss is then calculated as the maximum time necessary to
recover full work productivity for a given job position. This time
is referred to as the friction period, and costs to society are
assumed to be equal to zero after this period ends. The friction
period also includes the time necessary for training or initiating a
new worker [16–18].
The duration of the friction period varies widely in the
published literature. The duration often fails to reﬂect the local
characteristics of health care and social systems and rarely takes
the unemployment rate into consideration [15–17,19]. In partic-
ular, frictional unemployment should be of great interest.
We used a friction period of 6 months, that is, 130 workdays,
which was based on recommendations of the Czech Pharmacoe-
conomic Association [16]. The costs related to work productivity
loss were accordingly calculated using this period as the max-
imum time. We used the mean gross salary in the Czech Republic
for 2013 as the denominator in our calculations [20], which we
converted to euros (€45.4 per workday).
The calculation of productivity costs included patients of
productive or potentially productive age (18–64 years). Unem-
ployed patients, retired pensioners, and students were not
included. We included days spent on sick leave (up to a max-
imum equal to the friction period) and the period of time spent
on full disability pension or partial disability pension (again, up to
a maximum equal to the friction period). The information about
the productivity impairment was obtained by physicians on the
basis of their inquiry with patients at time 0 month, simulta-
neously with the HAQ score determination. Patients were ques-
tioned in terms of work/employment status, disability, and
number of days on sick leave in the previous 6 months.
The deﬁnition of “patient disability pension”was derived from
Czech law (Amendment of the Act no. 306/2008, Coll. of Acts, on
pension insurance). Full disability pension was deﬁned as work
productivity reduced by 70% and partial disability pension as work
productivity reduced by 52%.
Statistical Analysis
Descriptive statistics are presented as means  standard devia-
tions, and medians. The differences between groups were tested
by using the nonparametric Mann-Whitney test (two groups’
nominal data), the chi-square test (proportions of patients in
groups), and the Kruskal-Wallis test (more than two groups’
nominal data comparison). Test results were considered statisti-
cally signiﬁcant at Pr 0.05. Potential predictors of both direct and
overall costs were assessed by linear regression analyses on log-
transformed costs. The logarithmic transformation for costs was
Table 1 – Demographic characteristics and clinical parameters of the sample.
Demographic characteristic All patients
(N ¼ 261, 100%)
Without biologics
(n ¼ 137, 52.5%)
With biologics
(n ¼ 124, 47.5%)
P
Age (y)* 56.38  13.8 60 58.85  12.9 61 53.64  14.2 56 0.005†
Patients younger than 64 y 173 (66.3) 82 (59.9) 91 (73.4) 0.021‡
Women 220 (84.3) 137 (82.5) 124 (86.3) 0.398
Full-time work 78 (29.9) 44 (56.4) 34 (43.6) 0.408
Students 4 (1.5) 0 (0.0) 4 (100.0) 0.034‡
Old-age pensioners 87 (33.3) 48 (55.2) 39 (44.8) 0.54
Fully disabled patients§ 58 (22.2) 9 (15.3) 17 (29.8) 0.005†
Partially disabled patients§ 57 (21.8) 10 (18.2) 15 (25.8) 0.14
Information on disease
RA duration (y)* 14.5  10.2 14.0 13.6  11.6 11.0 15.5  8.4 15.0 0.002†
HAQ score* 1.15  0.81 1.12 1.12  1.00 0.88 1.18  1.17 0.74 0.314
DAS28 score* 3.45  1.52 3.53 3.35  1.56 3.06 3.56  1.48 3.43 0.099||
DAS28, Disease Activity Score in 28 joints; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis.
* Data are presented in the following format: mean  SD, median, or number (%).
† Statistical signiﬁcance at the 0.01 level.
‡ Statistical signiﬁcance at the 0.05 level.
§ Only for patients younger than 64 y.
|| Statistical signiﬁcance at the 0.10 level.
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nonlinear shape (reverse U-shape) and that is why we also
included squared age (age2), which allows more precise assess-
ment of costs in relation to age. Statistical analyses were
performed using the STATA 11.2 package (StataCorp, College
Station, TX).Results
Demography, Employment Status, and Clinical Parameters
Data were collected from consecutive patients coming for regular
outpatient visits to generate approximately the same size of
groups (50 patients) according to their HAQ score. Altogether,
261 patients were included in the analysis. Table 1 presents the
demographic characteristics of a sample for the whole cohort of
patients, for the subgroup of patients treated with biologics, and
for the subgroup without biologics (plus the comparison between
the two groups). Mean patient age was 56.4 years. Most patients
had a long history of the disease—the mean RA duration was 14.5Table 2 – Characteristics of the cohort by HAQ scores.
Parameter Patient g
o0.6 0.6–o1.1
No. of patients 69 54
Mean HAQ score 0.15 0.81
Mean DAS28 value 2.43 3.21
Mean age (y) 52.9 54.6
Proportion of women, n (%) 55 (79.7) 42 (77.8)
Time from diagnosis 11.0 12.5
Full employment, n (%)
Yes 38 (55.1) 18 (33.3)
Student 2 (2.89) 2 (3.7)
Old-age pensioner 16 (23.2) 19 (35.2)
DAS28, Disease Activity Score in 28 joints; HAQ, Health Assessment Que
* Statistical signiﬁcance at the 0.01 level.
† Statistical signiﬁcance at the 0.10 level.years. The cohort had 84% women. The mean value of the HAQ
score and the RA Disease Activity Score in 28 joints, for the
studied population, was 1.15 and 3.45, respectively.
A total of 29.9% of the patients were fully employed and 33.3%
were already receiving old-age pensions (some of these patients
were disabled before retirement). A total of 22.2% of the patients
younger than 64 years were already receiving a full disability
pension and 21.8% were receiving a partial disability pension.
Overall, 52.5% of the patients were treated with biologic
agents. Patients treated with biological drugs were younger (P ¼
0.005) and, at the same time, more disabled in terms of full
disability (P ¼ 0.005). Moreover, they had slightly longer disease
durations (P ¼ 0.065) and a higher proportion were students
(P ¼ 0.034).
Table 2 presents all the characteristics of the sample grouped
by the HAQ score: 1) o0.6, 2) 0.6 Z 1.1, 3) 1.1 Z 1.6, 4) 1.6 Z 2.1,
and 5) Z2.1. Each group of patients had a signiﬁcantly higher
mean Disease Activity Score in 28 joints (ranging from 2.64 to
4.41) and longer times since diagnosis (ranging from 15.1 to 22.9
years), with P o 0.001 for both; age was not statistically different
among groups and neither was the proportion of women. Fewerroups by HAQ scores P
1.1–o1.6 1.6–o2.1 Z2.1
58 38 42
1.27 1.84 2.42 0.000*
3.56 4.20 4.60 0.000*
57.3 60.0 59.8 0.065
†
51 (87.93) 34 (89.5) 38 (90.4) 0.250
14.9 16.7 20.0 0.000*
16 (27.5) 6 (15.8) 0 (0.0) 0.000*
0 (0.0) 0 (0.0) 0 (0.0) 0.321
25 (43.1) 15 (39.5) 12 (33.3) 0.144
stionnaire.
Table 3 – Resource use and mean direct and productivity annual costs (€) per patient by HAQ score.
Utilization Resource by HAQ score Annual costs per patient by HAQ score (€) P
o0.6 0.6–o1.1 1.1–o1.6 1.6–o2.1 Z2.1 o0.6 0.6–o1.1 1.1–o1.6 1.6–o2.1 Z2.1
DMARDs* 93% 87% 79% 79% 83% 474 437 396 373 522 0.519
Corticoids* 39% 56% 62% 74% 83% 11 20 24 29 47 0.000†
Biologic agents* 38% 52% 57% 50% 43% 4071 6080 6278 6243 4418 0.086‡
NSAIDs* 62% 44% 78% 68% 64% 29 18 32 21 26 0.037§
Total for drugs 4585 6554 6729 6666 5013 0.383
RA-associated hospital stays|| 1% 1/15 2% 1/1 5% 3/7.7 8% 3/7.3 40% 17/33.2 36 31 65 176 2330 0.000†
Rheumatologist, no. of visits 100% 2.5 100% 2.6 100% 2.3 100% 2.4 98% 2.5 211 221 200 209 202 0.695
Other specialists, no. of visits 65% 2.6 76% 2.8 79% 2.6 89% 2.5 83% 3.7 186 228 205 247 350 0.083‡
Physiotherapy, no. of procedures 4% 2.7 11% 4.5 16% 1.8 13% 4.2 12% 20.3 5 11 20 13 16 0.335
Spa therapy, no. of weeks 3% 4.0 4% 3.8 7% 3.2 8% 3.8 10% 3.5 51 65 98 138 146 0.574
X-ray 78% 2.0 81% 2.0 86% 2.0 82% 2.2 86% 4.4 98 110 112 124 246 0.012§
MRI 4% 1.0 0% – 9% 1.0 8% 1.0 12% 2.0 40 0 80 73 221 0.122
Ultrasound 38% 1.8 26% 1.8 24% 1.3 26% 1.6 33% 1.7 67 46 31 42 57 0.324
Other¶ 12% – 11% – 16% 13% – 33% – 7 7 9 12 49 0.015§
Surgery including inpatient stay 6% – 6% – 9% – 3% – 14% – 29 84 148 15 338 0.265
Total direct costs 5315 7357 7697 7716 8968 0.014§
Sick leave, mean no. of days# 12% 15 9% 21 10% 17 16% 35 0% – 78 89 68 250 0 0.181
Full disability pension# 4% – 17% – 21% – 32% – 52% – 179 688 854 1303 2161 0.000†
Partial disability pension# 38% – 22% – 22% – 11% – 5% – 1157 682 688 323 146 0.000†
Total productivity costs 1414 1459 1610 1876 2307 0.000†
Total costs 6730 8816 9307 9591 11274 0.014§
Resource use: First column in the respective HAQ group refers to the proportion of patients who consume the resource. Second column refers to the average number of units for patients who
consume the particular resource. P is related to costs and tests whether the mean value is equal among all ﬁve groups.
CT, computed tomography; DMARDs, disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire; MRI, magnetic resonance imaging; NSAIDs, nonsteroidal anti-
inﬂammatory drugs; RA, rheumatoid arthritis.
* Percentage of patients who used a certain drug.
† Statistical signiﬁcance at the 0.01 level.
‡ Statistical signiﬁcance at the 0.10 level.
§ Statistical signiﬁcance at the 0.05 level.
|| Average no. of hospital stays in the previous 12 mo/average no. of days in the previous 12 mo.
¶ Other means densitometry, CT, arthrography of the knee.
# Only for patients younger than 64 y.
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Table 4 – Unit costs in 2013 €.
Health care Unit Cost
Hospitalization 1 d 167
Rheumatologist 1 visit 85
Other specialist 1 visit 100
Rehabilitation 1 visit 8
Spa 1 wk 438
X-ray 1 examination 70
MRI 1 examination 928
Sonography 1 examination 100
MRI, magnetic resonance imaging.
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0.001). This was driven by two factors: 1) by increasing severity of
disease and its disabling nature and 2) by increasing age, as
patients drew closer to the natural retirement age.Health Resource Use and Direct Medical Costs
Table 3 presents a detailed description of use of all health
resources (resource consumption) for each of the HAQ groups,
representing annualized data (12 months). In addition, we pro-
vide unit costs for some of the most frequently items used in the
calculations (apart from drugs) (see Table 4).
With increasing disease severity (deﬁned by increasing HAQ
scores), there was clearly a higher probability of RA-associated
hospital stays; for example, 40% of the patients with HAQ scores
of 2.1 or more were hospitalized, on average, 2.44 times with an
average stay of 33.8 days. Patients visited the rheumatologist, on
average, about 2.5 times per year. Outpatient visits to other
specialists (apart from rheumatologists, e.g., cardiologist, oph-
thalmologist, etc.) were seen in greatest numbers (on average 3.7
times per year) for patients with HAQ scores of 2.1 or more. Also,
X-rays were most often associated with patients with HAQ scores
of 2.1 or more.Table 5 – Mean annual costs (€) per patient by HAQ score
of biologic agents.
Cost (in 2013 €) Patient
o0.6 0.6–o1.1
DMARDs 766 579
Corticoids 14 26
NSAIDs 26 9
Total for drugs 806 615
RA-associated hospital stays 76 62
Rheumatologist 207 211
Other specialist(s) 173 178
Physiotherapy 10 22
Spa treatment 106 130
X-ray 134 145
MRI 28 0
Ultrasound 18 26
Other‡ 10 10
Surgery þ hospital stays 53 149
Total 1621 1547
CT, computed tomography; DMARDs, disease-modifying antirheumat
resonance imaging; NSAIDs, nonsteroidal anti-inﬂammatory drugs; RA,
* Statistical signiﬁcance at the 0.01 level.
† Statistical signiﬁcance at the 0.10 level.
‡ Other means densitometry, CT, arthrography of the knee.Annual costs per patient for particular HAQ groups are also
presented in Table 3. From the total sum of direct costs,
expenditures for drugs represent the greatest amount, except
for the HAQ group of the most severe patients for whom the
greatest driver of costs was RA-associated hospital stays (repre-
senting 26% of all direct costs). Overall, drug expenditures did not
differ signiﬁcantly among HAQ score groups (P ¼ 0.383).
The costs associated with biological therapy (biologic agents)
represented 88% to 94% of the total mean costs for drugs per
patient per year; in terms of the total direct costs, biological
therapy represented 49% to 83%. Yet, the cost of biological
therapy does not differ among groups (P ¼ 0.086). However, we
can see that the costs of corticoids, nonsteroidal anti-
inﬂammatory drugs, RA-associated hospital stays, X-rays, full
disability pensions, and partial disability pensions were statisti-
cally different among HAQ groups.
We also provided an analysis of a subgroup of patients
without consumption of biologic agents. Table 5 presents a direct
cost analysis of these patients. Total direct costs for these
patients were substantially lower than for the whole patient
cohort mainly because of the extremely low costs for drugs,
which represented 50%, 40%, 34%, 37%, and 15% of total direct
costs, respectively, for each HAQ group: 1) o0.6, 2) 0.6 Z 1.1, 3)
1.1 Z 1.6, 4) 1.6 Z 2.1, 5) Z2.1. There was no difference in the
average cost for pharmacotherapy associated with increasing
HAQ scores (P ¼ 0.63); however, there was a rapid increase in
costs for hospital stays associated with RA (P ¼ 0.000) and X-rays
(P ¼ 0.004). For patients with HAQ scores of 2.1 or more, RA-
associated hospital stays represented almost 26% of the total
direct cost of the group. There was a mild increase in total direct
costs with increasing HAQ score, with an extreme jump in these
costs for patients with HAQ scores of 2.1 or more (nonetheless,
the groups’ costs still differed signiﬁcantly; P ¼ 0.001).
Productivity Impairment and Productivity Costs
Table 3 presents productivity impairment and productivity costs
for each HAQ group. The number of days on sick leave (short-termin the Czech Republic: Patients without consumption
groups by HAQ scores P
1.1–o1.6 1.6–o2.1 Z2.1
603 582 643 0.576
34 38 58 0.001*
13 17 20 0.088†
651 637 720 0.630
144 159 2156 0.000*
203 231 214 0.982
131 186 367 0.068†
45 23 23 0.183
219 250 204 0.742
157 127 299 0.004*
107 88 278 0.237
15 29 40 0.436
13 11 57 0.282
203 0 387 0.199
1889 1740 4747 0.001
ic drugs; HAQ, Health Assessment Questionnaire; MRI, magnetic
rheumatoid arthritis.
Table 6 – Overall annual costs per patient (in 2013 €).
Cost All patients Patients without biological
treatment
Patients with biological
treatment
P
Direct costs 7,204  6,068 5,811 2,255  2,536 1,447 12,673  3,645 12,926 0.0000*
Productivity costs 1,678  1,895 0 1,304  1,830 0 2,090  1,888 3,070 0.0004*
Total costs 8,882  6,710 8,162 3,559  3,347 3,004 14,763  4,044 14,433 0.0000*
Note. Data are presented in the following format:
mean  SD, median.
* Statistical signiﬁcance at the 0.01 level.
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leading to absence from paid work) was relatively small and
trended downward with higher HAQ scores. This phenomenon
can be accounted for by the difference in working status asso-
ciated with higher HAQ scores; that is, patients with HAQ scores
of more than 2.1 had zero days of sick leave because none was
fully employed. The proportion of those receiving a disability
pension increased with higher HAQ scores.
Overall, there were 58 (22.2%) patients on a full disability
pension (aged 64 years or younger) and 57 patients (21.8%) were
on a partial disability pension (aged 64 years or younger); more
details are presented in Tables 1, 2, and 3. At the same time, it
was possible to show that patients from our study groups were
more than ﬁve times more likely to be disabled (5.4 times)
compared with the general population (aged 20–64 years) in the
Czech Republic [21]. Total mean productivity costs per patient
increased with increasing HAQ scores (P o 0.001).
Overall Costs
The last row of Table 3 provides the total costs by HAQ group; the
costs, as expected, increased with the HAQ score and were
statistically different (P ¼ 0.014). Table 6 presents the total mean
annual cost per patient with RA that had to be covered by health
care payers (i.e., direct costs) and the cost related to work
productivity loss (i.e., productivity costs). In addition, we com-
pared the cost of patients with and without biological treatment;
as expected, direct, productivity, and total costs were signiﬁ-
cantly higher (P o 0.001) in patients with biological treatment of
RA. Figure 1 shows the overall and breakdown mean annual costs
per patient according to functional impairment.
Cost Predictors
To determine cost predictors (only direct and total costs because
productivity costs were equal to zero in 135 of 261 cases), weFig. 1 – Overall and breakdown mean annual costs per patient a
disease-modifying antirheumatic drugs; HAQ, Health Assessmen
nonsteroidal anti-inﬂammatory drugs.performed a linear regression analysis using log-transformed
costs as the dependent variable. HAQ, time from diagnosis, age
and age2, sex, and an indicator of biologic treatment were used as
independent variables. The results in Table 7 present that the
HAQ score (P o 0.001), age2 (P ¼ 0.013), biological treatment (P o
0.001), and years since diagnosis (P ¼ 0.001) were signiﬁcant
predictors of overall costs. Interestingly, costs increased with age
but from the age of 67.8 years costs started to decrease; that is,
costs exhibited a reverse U shape and for this reason we included
age2 as a potential predictor. When analyzing direct costs, HAQ
scores and biological treatment were statistically signiﬁcant (P o
0.001 for both) as well as years since diagnosis (P ¼ 0.002). To
conclude, a patient on biological treatment had 4.28 times the
total costs and 6.44 times the direct costs of a patient without this
treatment while controlling for other variables (age, sex, time
since diagnosis, etc.). Moreover, an increase in the HAQ score by 1
increased direct costs by 29% and total costs by 32%; each
additional year of disease duration led to a mean increase of
13% in both direct and total costs.Discussion
This article provides a description of the care and resource
consumption for patients with RA grouped according to their
HAQ scores (functional impairment) in the Czech Republic.
The costs were divided into health care costs and costs
attributed to productivity loss. Possible limitations of this
cost-of-illness study were that out-of-pocket expenditures
and productivity lost by families and/or friends (informal
caregivers) relative to other societal costs of RA were not
included.
In terms of direct (medical) costs, we found HAQ scores and
treatment with biologics to be signiﬁcant predictors. Although
these costs are poorly predicted by age, they can be reliablyccording to functional impairment (HAQ category). DMARDs,
t Questionnaire; MRI, magnetic resonance imaging; NSAIDs,
Table 7 – Cost predictors, results of the linear
regression models.
Parameter ln direct costs ln total costs
Coefﬁcient SE Coefﬁcient SE
HAQ score 0.256* 0.057 0.279* 0.054
Female 1.214 0.103 0.026 0.116
Age 0.005 0.003 0.0346† 0.020
Age2 0.0005* 0.000
Biologics 2.008* 0.070 1.665* 0.075
Years from
diagnosis 0.126* 0.004 0.136* 0.004
Constant 10.502* 0.190 10.192* 0.528
R2 0.781 0.713
Robust
errors Yes Yes
N 261 261
HAQ, Health Assessment Questionnaire; ln, natural log; SE,
standard error.
* Statistical signiﬁcance at the 0.01 level.
† Statistical signiﬁcance at the 0.10 level.
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overall costs, we found that HAQ scores, treatment with biologics,
age, and age2 (all led to increasing cost) should be taken into
account when predicting the extent of these costs.
Moreover, we found that productivity costs were signiﬁcantly
higher for patients with higher HAQ scores (Table 3). Within our
study, productivity costs represented 18.9% of the total costs
(whole cohort study group), with 36.6% in patients without bio-
logic treatment and 14.2% in patients on biological agents
(Table 6). These percentages are lower compared with ﬁndings
in some articles that describe the percentage of productivity costs
to be up to 75% of total costs [5,6]. This difference was mainly
linked to the methodology we used, because we calculated
productivity costs according to the friction cost approach, which
produces different results than does the human capital approach.
From the societal perspective, we ﬁnd the friction cost approach
to be a more suitable approach for describing productivity loss
from a macroeconomic point of view compared with the human
capital approach, which tends to focus on the microeconomic
perspective [16].
One limitation of our productivity costs calculation was that
only absenteeism was studied (short- and long-term absenteeism
and early retirement expressed as a full or partial disability
pension); no presenteeism was assessed. There is still, however,
a lot of debate on how to describe productivity loss in monetary
values [22].
Next, an issue that should be stressed in our study is that
costs directly related to RA were included, with the exception of
osteoarthritis. It was almost impossible to distinguish whether
resources consumed should be attributed only to RA or to its
directly related comorbidity, osteoarthritis. Even though there are
other comorbidities that are prevalent in those with RA, for
example, metabolic syndrome [23,24], costs associated with the
treatment of cardiovascular diseases and other comorbidities
were not included.
In conclusion, the results from our study provided useful
inputs into health-economic modeling of cost-effectiveness
within the diagnosis of RA, particularly in the Czech Republic.Source of ﬁnancial support: This work was supported by Ministry
of Health of Czech Republic (grant no. 000 000 23728) and the Charles
University, Prague, Czech Republic (grant no. SVV 260 066).
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